Lecturer Prof. Gal Markel

Contact michal.av@weizmann.ac.il

Abstract Personalized medicine in oncology is focused on fitting drugs to the appropriate patients, mainly by identifying unique mutations in tumor genomics and development of highly selective drugs. The main challenge is that the relevant populations grow smaller, while development costs are constant, leading to significant reduction in effective drug development. The immune system provides personalized anti cancer response, and immune checkpoint inhibitors enable decent responses over a wide array of tumors. The outstanding challenge is that efficacy is observed in less than a third of the patients. Here we explore strategies to alter the patient in a way that will enable standard of care immunotherapy to exert its full potential, i.e. fitting the patients to the existing immunotherapeutic medications.

Details Ella Lemelbaum Institute, Sheba Medical Center